

**ONCOLOGY RESEARCH INTERNATIONAL  
LIMITED**

**ACN 067 964 621**

**NOTICE OF ANNUAL GENERAL MEETING**

**DATE AND TIME OF MEETING**

*Tuesday 29<sup>th</sup> November 2016 at 2.30 pm*

**PLACE OF MEETING**

*Level 5  
45 St George's Terrace  
PERTH WA 6000*

**ONCOLOGY RESEARCH INTERNATIONAL LIMITED  
ACN 067 964 621**

**NOTICE OF ANNUAL GENERAL MEETING**

**NOTICE IS HEREBY GIVEN** that the Annual General Meeting of the members of Oncology Research International Limited will be held at Level 5, 45 St George's Terrace, Perth, Western Australia, 6000 on Tuesday 29<sup>th</sup> November 2016 at 2.30pm for the purpose of transacting the business set out below:

**AGENDA**

**RESOLUTION 1: Financial Statements and reports for the 2016 year**

To receive, consider and adopt the financial report for the year ended 30 June 2016 and reports by Directors and Auditors thereon.

**OTHER BUSINESS**

1. Address by Chairman Of the Board
2. Address by Chief Executive Officer
  - Overview of significant developments
  - Review of existing research program
  - Outline of research program for the next 12 months
3. General Discussion

Meeting open to shareholders to direct questions to the Directors.

**BY ORDER OF THE BOARD**



---

**Kenneth Michael Wayte**  
Director/Secretary

## PROXY AND VOTING ENTITLEMENT INSTRUCTIONS

### PROXIES

Shareholders are entitled to appoint up to two individuals to act as proxies to attend and vote on their behalf. Where more than one proxy is appointed each proxy may be appointed to represent a specific proportion of the member's voting rights. If the appointment does not specify the proportion or number of votes each proxy may exercise, each proxy may exercise half of the votes.

The proxy form (and the power of attorney or other authority, if any, under which the proxy form is signed) or a copy or facsimile which appears on its face to be an authentic copy of the proxy form (and the power of attorney or other authority) must be deposited at or sent by facsimile transmission to the registered office of the Company at Level 5, 45 St George's Terrace, Perth, Western Australia, 6000 facsimile number +61 (8) 9481 0152 **at least 48 hours prior to the meeting**, or adjourned meeting as the case may be, at which the individual named in the proxy form proposes to vote.

The proxy form must be signed by the shareholder or his/her attorney duly authorised in writing or, if the shareholder is a corporation, in a manner permitted by the Corporations Act 2001. The proxy may, but need not, be a shareholder of the Company.

In the case of shares jointly held by two or more persons, all joint shareholders must sign the proxy form.



**K M Wayte**  
**Director/Secretary**

**Oncology Research International Limited**  
**ACN 067 964 621**  
**PROXY FORM**

The Company Secretary  
Oncology Research International Limited  
Level 5  
45 St George's Terrace  
PERTH WA 6000

Facsimile: +61 8 9481 0152

I/We \_\_\_\_\_

of \_\_\_\_\_

being a member/(s) of Oncology Research International Limited (the "Company")

hereby appoint \_\_\_\_\_

of \_\_\_\_\_

or in his/her absence \_\_\_\_\_

of \_\_\_\_\_

or failing him/her the Chairman as my/our proxy to vote for me/us and on my/our behalf at the Annual General Meeting of the Company to be held at Level 5, 45 St George's Terrace, Perth, Western Australia, 6000, on Tuesday 29<sup>th</sup> November 2016 at 2.30 pm and at any adjournment of that meeting.

If you wish to indicate how your proxy is to vote, please tick the appropriate place below. If no indication is given, the proxy may abstain or vote at his or her discretion.

I/we direct my/our proxy to vote as indicated below:

		For	Against	Abstain
Resolution 1	Receipt and adoption of the 2016 Financial Statements	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

As witness my/our hand/s this \_\_\_\_\_ day of \_\_\_\_\_ 2016

**If a natural person:**

SIGNED by \_\_\_\_\_  
Signature

\_\_\_\_\_  
Signature (if joint holder)

**If a Company**

THE COMMON SEAL of

\_\_\_\_\_  
was affixed in the  
presence of:

\_\_\_\_\_  
Signature of Director

\_\_\_\_\_  
Signature of Director/Secretary

## ELECTRONIC COMMUNICATION

In the interest of managing costs and for speed of communication, you now have the option of receiving communications from the Company by way of email.

Please note that if you choose to receive communications electronically, you may no longer receive paper copies of communications.

Should you wish to receive communications from the Company by email, please tick the following box and provide your email address.

**I elect where possible, that all future communications from the company be made by email.**

**My email address is:** \_\_\_\_\_

**My shares are held in the name of:** \_\_\_\_\_

\_\_\_\_\_

If you elect to receive communications electronically please return the completed form to the registered office of the Company at Level 5, 45 St George's Terrace, Perth, Western Australia, 6000 facsimile number +61 (8) 9481 0152.